布拉迪基宁在患有心力衰竭的狗身上保持了血管扩张作用
1Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 400, Faculté de Médecine, Créteil, France. jbsu@im3.inserm.fr
Circulation
|December 22, 1998
概括
在心力衰竭中,布拉迪基宁的血管扩展效应是保留的,尽管的内皮衍生的血管扩张. 这表明布拉迪基宁在心力衰竭中控制血管收缩起着关键作用.
科学领域:
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 的特征是激活的血管收缩系统和的内皮衍生的血管扩张.
- 布拉迪基宁在HF中扮演的角色,它是一种强大的血管扩张剂,目前尚不清楚.
研究的目的:
- 在心力衰竭模型中调查布拉迪基宁的血管扩展效应是否被修改.
主要方法:
- 研究慢性仪器犬在控制状态和节奏诱导的HF.
- 用外源布拉迪基宁和乙胆来评估血管扩张.
- 使用埃纳拉普利拉特和西普罗基伦评估内源勃拉迪基宁效应,有或没有Hoe 140 (勃拉迪基宁B2受体对抗剂).
主要成果:
- 在HF中,乙胆诱导的血管扩张被减弱.
- 外源布拉迪基宁在对照和高频率中引起了相似的剂量依赖的平均大动脉压力 (MAP) 降低和心脏输出量 (CO) 增加.
- 通过埃纳拉普利拉特评估的内源勃拉迪基宁效应在HF中被保留,类似于对照.
结论:
- 外源和内源布拉迪基宁的血管扩张作用在这个HF模型中被保留.
- 布拉迪基宁可能在高血压中发挥显著的补偿作用,抵消血管收缩和的内皮依赖血管扩张.
相关概念视频
Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626


